Aridis Pharmaceuticals Expands the Company's Clinical Advisory Board; Adds Three Industry Veterans with Unique Expertise in the Field

SAN JOSE, Calif., July 11, 2016 /PRNewswire/ -- Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today the addition of three highly recognized experts, Bruno Francois, M.D., Jean Chastre, M.D., and Marin Kollef, M.D., F.A.C.P., F.C.C.P., to the company's Clinical Advisory Board. These world-renowned authorities in hospital-acquired and ventilator-associated pneumonia (HAP and VAP) and infectious disease in the intensive care medicine (ICU) setting are bringing their experience and knowledge to help drive Aridis' leading edge clinical programs forward.

Paul-Andre de Lame, M.D., Chief Medical Officer of Aridis, stated, "We are honored to see such esteemed key opinion leaders in pneumonia join our Clinical Advisory Board. Their collaborative clinical expertise, achievements and experience within Aridis' primary area of focus will not only help maximize the value of our current pipeline, but will also serve as an invaluable resource for the development and success of our current and future programs."

Dr. Francois, a specialist in intensive care medicine and anesthesiology, heads the Limoges Clinical Investigation Center with a specific focus on infectious diseases in critically ill patients at the University Hospital of Limoges, France. He has participated in several advisory boards for Sepsis and VAP multinational trials, independent clinical evaluation committees and adjudication committees. He is also the author of multiple publications and a reviewer for medical journals focused on infectious disease in the ICU.  He is currently investigating the role of bacterial resistance mechanisms and integrons during Sepsis with the Marie-Cécile Ploy Inserm research team from Limoges, France. He created the CRICS network dedicated to clinical research in Sepsis trials in 2007 and is now co-leading the French TRIGGERSEP research network (F-CRIN certification within ECRIN), which integrates all research activities in Sepsis from basic science to clinical trials. He is also coordinating the COMBACTE consortium within the IMI framework and leading the SAATELLITE trial in collaboration with Medimmune since 2012.

Dr. Chastre, Consulting Professor in the Medical ICU and former director of the same ICU at Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière in Paris, France, also served as a member of the Clinical Advisory Board at Kenta Biotech AG (formerly Kenta Biotech Ltd.). He is a recognized expert in the performance of clinical outcomes research in the ICU setting and his clinical research focus has been the understanding, diagnosis and treatment of nosocomial infections and the improved care of mechanically ventilated patients. He is also a professor of medicine at Paris 6 University School of Medicine, Faculté de Médecine Pitié-Salpêtrière, France, and has published more than 170 peer-reviewed papers and authored or co-authored 18 book chapters. He earned his fellowship in cardiology and critical care and is licensed and board certified in cardiology with a subspecialty in critical care.

Dr. Kollef is the director of the medical intensive care unit and respiratory care services at Barnes-Jewish Hospital in St. Louis, Missouri. He is also a professor of medicine at Washington University, School of Medicine, and has lectured on numerous critical care topics such as fungal infection, VAP, antibiotic resistance and antibiotic therapy optimization. He serves on the editorial boards of numerous medical journals, such as Respiratory Care, Critical Care and Journal of Surgical Infections. He is the recipient of various honors and awards, including selection to "Best Doctors in America," central region and Barnes-Jewish Hospital team awards for quality improvement for programs directed to VAP prevention, bloodstream infection prevention and the "Surviving Sepsis Initiative." His awards for military service with the First Infantry Division during operation Desert Storm include Bronze Star, Meritorious Service Medal and Combat Medical Badge in support of combat operations. He is also a member of multiple organizations in his field and chair for the Global Anti-Infectives Leadership Academy.

About Aridis Pharmaceuticals, Inc.
Aridis is a privately held biopharmaceutical company applying its proprietary monoclonal antibody discovery technology MabIgX™ to produce novel infectious disease focused therapies.  Aridis' product pipeline includes AR-101 (Aerumab™) anti-Pseudomonas aeruginosa LPS human monoclonal antibody; AR-301 (Salvecin™) anti-Staphylococcus aureus human monoclonal antibody to treat acute pneumonia; Aerucin™, a broadly reactive anti-Pseudomonas aeruginosa human monoclonal antibody initially being developed to treat acute pneumonia; Panaecin™, a small molecule anti-infective gallium compound with broad spectrum activities against bacteria, viruses, and fungi; AR- 401 anti-Acinetobacter baumannii human monoclonal antibody; and AR-201 anti-RSV human monoclonal antibody.

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties.  Such forward-looking statements include statements relating to the therapeutic applications of Aerumab™ (AR-101), Salvecin™ (AR-301), Aerucin™, Panaecin™, AR-401, AR-201, Aridis' proprietary formulation and delivery technologies, about Aridis' strategy, pre-clinical and clinical programs, and ability to identify and develop drugs, as well as other statements that are not historical facts. Actual events or results may differ materially from Aridis' expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Aridis' research and clinical studies and its ability to obtain additional financing.  These forward-looking statements represent Aridis' judgment as of the date of this release. Aridis disclaims any intent or obligation to update these forward-looking statements.

Contacts:

Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (investors)
[email protected]
(212) 375-2664

Andrew Mielach (media)
[email protected]
(212) 375-2694

SOURCE Aridis Pharmaceuticals, Inc.